Alerts will be sent to your verified email
Verify Email
UNICHEMLAB
|
Unichem Lab
|
Sequent Scientific
|
Guj. Themis Biosyn
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceutical Sector
|
|||
|
Number of ANDA's Filed in USA
|
41.0 . | n/a | n/a |
|
Number of ANDA's Approved By USFDA
|
27.0 . | n/a | n/a |
|
R&D as a % of Total Sales
|
5.35 % | 0.0 | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
-0.79 % | -0.13 % | 41.95 % |
|
5yr average Equity Multiplier
|
1.32 | 2.16 | 1.37 |
|
5yr Average Asset Turnover Ratio
|
0.47 | 0.95 | 0.89 |
|
5yr Avg Net Profit Margin
|
-1.68 % | 0.03 % | 34.6 % |
|
Price to Book
|
1.75 | 5.98 | 16.31 |
|
P/E
|
31.15 | 192.63 | 90.85 |
|
5yr Avg Cash Conversion Cycle
|
88.84 Days | 49.09 Days | -31.8 Days |
|
Inventory Days
|
151.32 Days | 80.25 Days | 23.52 Days |
|
Days Receivable
|
122.86 Days | 79.76 Days | 48.29 Days |
|
Days Payable
|
205.05 Days | 114.46 Days | 135.34 Days |
|
5yr Average Interest Coverage Ratio
|
2.41 | 1.93 | 187.52 |
|
5yr Avg ROCE
|
1.04 % | 6.67 % | 54.74 % |
|
5yr Avg Operating Profit Margin
|
5.43 % | 7.74 % | 45.69 % |
|
5 yr average Debt to Equity
|
0.11 | 0.53 | 0.05 |
|
5yr CAGR Net Profit
|
32.0 % | -25.52 % | 20.11 % |
|
5yr Average Return on Assets
|
-0.65 % | 0.05 % | 30.29 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
70.22 % | 52.61 % | 70.86 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
19.29 % | -0.18 % | -4.13 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
1.31 % | 9.79 % | 1.14 % |
|
Unichem Lab
|
Sequent Scientific
|
Guj. Themis Biosyn
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
-
|